FindMyRecallSubscribe
Class I: serious health riskTerminated

Novo Nordisk Xultophy 100/3 Recall

Xultophy 100/3

Novo Nordisk Inc · Plainsboro, NJ

Risk level
Class I
Reported by FDA
Apr 21, 2021
Recall ID
D-0623-2021
Check your lot numberHow we source this data

Summary

Novo Nordisk recalled Xultophy 100/3 starting Mar 22, 2021. The FDA classified it as Class I (serious health risk) and published enforcement report D-0623-2021 on Apr 21, 2021. Reason: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors. Status: Terminated.

Why it was recalled

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Product description

Xultophy 100/3.6 (insulin degludec and liraglutide injection), 100 units/mL and 3.6 mg/mL, 3 mL Prefilled Pen, SAMPLE, Rx only, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, Distributed by: Novo Nordisk Inc, Plainsboro, NJ 08536, NDC 0169-2911-90 (Pen) NDC 0169-2911-97 (Kit)

Lot numbers, UPCs & expiration codes

JP54291, exp 06/20/2021

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0623-2021
Classification
Class I
Status
Terminated
Recall initiated
Mar 22, 2021
FDA report date
Apr 21, 2021
Quantity
N/A
Recall type
Voluntary: Firm initiated
Recalling firm
Novo Nordisk Inc

Original FDA data

Every field from FDA enforcement report D-0623-2021, exactly as published.

Show all FDA fields
City
Plainsboro
State
NJ
Status
Terminated
Country
United States
Event ID
87537
Address
800 Scudders Mill Rd
Code information
JP54291, exp 06/20/2021
Postal code
08536-1606
Report date
Apr 21, 2021
Product type
Drugs
Recall number
D-0623-2021
Classification
Class I
Recalling firm
Novo Nordisk Inc
Termination date
Dec 9, 2022
Reason for recall
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Xultophy 100/3.6 (insulin degludec and liraglutide injection), 100 units/mL and 3.6 mg/mL, 3 mL Prefilled Pen, SAMPLE, Rx only, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, Distributed by: Novo Nordisk Inc, Plainsboro, NJ 08536, NDC 0169-2911-90 (Pen) NDC 0169-2911-97 (Kit)
Distribution pattern
Nationwide in the USA
Recall initiation date
Mar 22, 2021
Initial firm notification
Letter
Center classification date
Jun 10, 2021

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0623-2021, published Apr 21, 2021. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls